Abstract: A method of applying a hierarchical porous ZrO2 includes: dissolving a triblock copolymer in an organic solvent to obtain a solution A, dissolving a tannin extract in distilled water to obtain a solution B, mixing the solution A and the solution B and stirring to obtain a mixed solution; adding a zirconium salt to the mixed solution and stirring; heating the mixed solution in an oven to obtain ZrO2, promoting the conversion of the crystal form of ZrO2; calcining ZrO2 at a high temperature to obtain the hierarchical porous ZrO2; mixing the hierarchical porous ZrO2 with a solution containing a lysozyme protein; and absorbing the lysozyme protein to the hierarchical porous ZrO2.

Abstract: A compound having the following formula (I): is disclosed. The methods of preparing the compound of formula (I) are also disclosed.

Abstract: A compound having the formula (I): is disclosed. A method of preparing the compound of formula (I) is also disclosed.

Abstract: A compound with antibacterial activity having the following formula (I): is disclosed. A method of preparing the compound of formula (I) is also disclosed.

Abstract: A compound with anti-drug resistant bacteria activity having the following formula (I): is disclosed. A method of preparing the compound of formula (I) is also disclosed.

Abstract: A method of preparing a compound of formula (I): is disclosed. The compound of formula (I) can be used as an antioxidant agent. The compound can also be used as an antibacterial agent to inhibit Staphylococcus aureus 18-596 and Staphylococcus aureus 18-596.

Abstract: A method of inhibiting leukotriene include: administrating a therapeutically effective amount of a compound of chemical formula I or II or a pharmaceutical acceptable salt thereof to a subject, R1 is OH or OAc; X is C or N; and R2 is H, alkyl, alkoxy, benzyloxy, haloalkyl, OH, CN, NO2, or halogen, provided that when X is N, R2 is nil.

Abstract: A method of inhibiting leukotriene, treating asthma, or treating inflammation includes: administrating to a subject a therapeutically effective amount of a compound of chemical formula I or II: or a pharmaceutical acceptable salt thereof. R1, R2, R3, and R4 are independently H, halogen, nitro, hydroxyl, cyano, benzyloxy, C1-C8 straight or branched alkyl, C1-C8 straight or branched haloalkyl, C1-C8 straight or branched alkoxy.

Abstract: A method of preparing 6-chloro-5-nitro-2,4-diaminopyrimidine includes: reacting guanidine hydrochloride with ethyl carbamoylacetate and sodium hypochlorite in the presence of a metal nitrate salt and acetate anhydride in an organic solvent.